Overview

Fruquintinib Combined With TAS-102 Versus Bevacizumab Combined With TAS-102 for Advanced Metastatic Colorectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2029-12-31

Target enrollment:

Participant gender:

Summary

Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with chemotherapy. Trifluridine/tipiracil (TAS-102) plus bevacizumab is also a standard treatment for mCRC. This study aims to explore the efficacy and safety of fruquintinib combined with TAS-102 versus bevacizumab combined with TAS-102 in the treatment of patients with advanced metastatic colorectal cancer who failed standard chemotherapy.

Phase:

PHASE2

Details

Lead Sponsor:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Treatments:

trifluridine tipiracil drug combination